











Available in the following panels:

	LUCENCE INSIGHT™ PLUS	LUCENCE INSIGHT™
 LUNG	✓	✓
 BREAST	✓	✓
 COLORECTAL	✓	✓
 PROSTATE	✓	✓
 LIVER	✓	✓
 NOSE	✓	✓
 BILE DUCT	✓	✓
 PANCREAS	✓	✓
 ACUTE MYELOID LEUKEMIA	✓	
 CHRONIC MYELOID LEUKEMIA	✓	

LucenceINSIGHT™ PLUS also covers the following





CHIP*	✓
-------	---

* Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related bone marrow phenomenon associated with both an increased risk of developing cardiovascular disease and hematologic cancers.

References

1. American Cancer Society. <https://www.cancer.org>
2. National Cancer Institute. <https://seer.cancer.gov/>
3. Substantiation available upon request.

How does LucenceINSIGHT™ work?

-  2 tubes of blood (~18mL) are required.
-  Evaluates the risk of 10 common types of cancer in Asia, including lung, breast and the colorectum.
-  Proprietary Next Generation Sequencing approach to increase screening sensitivity.
-  Screening for viruses such as EBV (Epstein-Barr virus) which is an associated pathogen of cancer.

This pamphlet is not intended for the purpose of providing medical advice.

All information, content, and material of this pamphlet are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.

Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

Customer support: +65 6592 5102 | sales.asean@lucence.com

Lucence Service Laboratory

211 Henderson Road #04-01/02, Henderson Industrial Park, Singapore 159552

Lucence Diagnostics Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (Licence Number: L/1710039/CLB/003/222) under the Healthcare Services Act 2020. GST Registered 201605840N.

© 2023 Lucence Diagnostics Pte. Ltd. All Rights Reserved.

lucence.com

M6002E-SG-01. February 2023

Your Multi-Cancer Early Screen

Early Detection
Saves Lives.
Get an **INSIGHT** into
Your Health Today.




Why should we screen for cancer?

Because disease happens before symptoms. Cancer symptoms often do not visibly appear in the body until later.


Cancer can affect any of us. 1 in 2 women and 1 in 3 men will develop cancer in their lifetime¹.

Detecting cancer early enough can make a difference. This is because cancer is easiest to treat when it is found early.

Colorectal cancer survival rate by stage²




Breast cancer survival rate by stage²



What is LucenceINSIGHT™?

LucenceINSIGHT™ is a multi-cancer screening tool that screens for the risk of multiple cancers in one simple blood draw.



LucenceINSIGHT™ is based on a proprietary amplicon-based technology to screen for the risks of cancer with a sensitivity of 73% and a specificity of 96%³.

The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%³.

Sensitivity

73%

Specificity

96%

Tumor Origin
Prediction

90%

LucenceINSIGHT™ is recommended for use in conjunction with existing screening tools for individuals without a personal history of cancer.

What results can I expect?

If your result shows a "Cancer Risk **High**"?

Recommended to consult your doctor for further evaluation.

If your result shows a "Cancer Risk **Low**"?

To continue following routine screening recommended by your healthcare provider.

Who can benefit from multi-cancer screening?

- Individuals aged 40 and above, or
- Individuals with an elevated risk for cancer e.g. family history of cancer, diet, lifestyle and more.

